Holding its ground above its 50 DMA line and prior highs, consolidating after a recent streak of volume-driven gains. Last noted in the 4/11/13 mid-day report with caution - "Sales revenues and earnings improved in the Sep and Dec '12 quarterly comparisons versus the year ago periods. This Medical - Products firms prior earnings history is not a match with the fact-based investment system's guidelines (C and A criteria). Low-priced stocks are discouraged from consideration unless all key criteria are solidly satisfied."
Retreating from its 52-week high today following a streak of 4 consecutive gains with above average volume. Held its ground stubbornly after a recent streak of gains, yet prior mid-day reports repeatedly cautioned - "Sales revenues and earnings improved in the Sep and Dec '12 quarterly comparisons versus the year ago periods. This Medical - Products firms prior earnings history is not a match with the fact-based investment system's guidelines (C and A criteria). Low-priced stocks are discouraged from consideration unless all key criteria are solidly satisfied."
Hitting another new 52-week high with above average volume behind today's 4th consecutive gain. Held its ground stubbornly after a recent streak of gains, yet prior mid-day reports repeatedly cautioned - "Sales revenues and earnings improved in the Sep and Dec '12 quarterly comparisons versus the year ago periods. This Medical - Products firms prior earnings history is not a match with the fact-based investment system's guidelines (C and A criteria). Low-priced stocks are discouraged from consideration unless all key criteria are solidly satisfied."
Hitting another new 52-week high today. Held its ground stubbornly after a recent streak of 7 consecutive gains. Noted in prior mid-day reports with caution - "Sales revenues and earnings improved in the Sep and Dec '12 quarterly comparisons versus the year ago periods. This Medical - Products firms prior earnings history is not a match with the fact-based investment system's guidelines (C and A criteria). Low-priced stocks are discouraged from consideration unless all key criteria are solidly satisfied."
Hit a new 52-week high today with a gap up while on track for a 6th consecutive gain. Last noted in the 3/18/13 mid-day report with caution - "Sales revenues and earnings improved in the Sep and Dec '12 quarterly comparisons versus the year ago periods. This Medical - Products firms prior earnings history is not a match with the fact-based investment system's guidelines (C and A criteria). Low-priced stocks are discouraged from consideration unless all key criteria are solidly satisfied."
Sales revenues and earnings improved in the Sep and Dec '12 quarterly comparisons versus the year ago periods. This Medical - Products firms prior earnings history is not a match with the fact-based investment system's guidelines (C and A criteria). Low-priced stocks are discouraged from consideration unless all key criteria are solidly satisfied.